Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 43 and last traded at GBX 44.88, with a volume of 287907 shares. The stock had previously closed at GBX 45.40.
Faron Pharmaceuticals Oy Price Performance
The stock has a market capitalization of £51.96 million, a price-to-earnings ratio of -1.66 and a beta of 1.09. The company has a 50 day moving average of GBX 116.72 and a 200 day moving average of GBX 161.13. The company has a quick ratio of 1.09, a current ratio of 0.84 and a debt-to-equity ratio of -133.35.
Insider Activity at Faron Pharmaceuticals Oy
In other news, insider Jurriaan Dekkers sold 4,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of GBX 182, for a total transaction of £7,280. 3.94% of the stock is currently owned by corporate insiders.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
Further Reading
- Five stocks we like better than Faron Pharmaceuticals Oy
- The “secret weapon” behind Microsoft, Meta, Amazon, and Google
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- The U.S. Military’s “Ace Card” For Iran
- Iran isn’t the real war
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
